Clinical trial
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard…
NCT03412565 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT03412565 |
|---|---|
| Title | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens |
| Official title | A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib |
| Enrollment | 265 |
| Start date | Apr 26, 2018 |
| Primary completion | Aug 12, 2020 |
| Completion | Apr 18, 2024 |
| First posted | Jan 26, 2018 |
| Last update posted | Apr 29, 2025 |
| Countries | Brazil, Czechia, France, Germany, Israel, Japan, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: